These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28943185)

  • 1. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
    Brzezniak C; Oronsky B; Aggarwal R
    Eur Urol; 2018 Feb; 73(2):306-307. PubMed ID: 28943185
    [No Abstract]   [Full Text] [Related]  

  • 2. Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma.
    Lee MJ; Tomita Y; Yuno A; Lee S; Abrouk NE; Oronsky B; Caroen S; Trepel JB
    Expert Opin Investig Drugs; 2021 Feb; 30(2):177-183. PubMed ID: 33306414
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.
    Ojemuyiwa M; Zeman K; Spira A; Oronsky B; Ray C; Trepel JB; Lee MJ; Onyiuke I; Brzezniak C
    Clin Case Rep; 2018 Dec; 6(12):2478-2481. PubMed ID: 30564353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
    Zafeiriou Z; Bianchini D; Chandler R; Rescigno P; Yuan W; Carreira S; Barrero M; Petremolo A; Miranda S; Riisnaes R; Rodrigues DN; Gurel B; Sumanasuriya S; Paschalis A; Sharp A; Mateo J; Tunariu N; Chinnaiyan AM; Pritchard CC; Kelly K; de Bono JS
    Eur Urol; 2019 Jan; 75(1):184-192. PubMed ID: 30340782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.
    Brzezniak C; Oronsky B; Scicinski J; Caroen S; Cabrales P; Dean Abrouk N; Kim MM; Brown JF; Reid TR; Larson C; Oronsky A; Day R; Degesys A; Carter CA
    Oncol Res Treat; 2016; 39(11):720-723. PubMed ID: 27855386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
    Dorff TB; Wilkins C; Hepgur M; Quinn DI
    Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 8. Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.
    Kim MM; Parmar H; Cao Y; Knox SJ; Oronsky B; Scicinski J; Lawrence TS; Lao CD
    Neuro Oncol; 2016 Mar; 18(3):455-6. PubMed ID: 26769715
    [No Abstract]   [Full Text] [Related]  

  • 9. Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer.
    Hutson PR
    Clin Pharmacokinet; 2015 Oct; 54(10):989-91. PubMed ID: 26077984
    [No Abstract]   [Full Text] [Related]  

  • 10. Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix.
    Tangjitgamol S; Manusirivithaya S; Choomchuay N; Leelahakorn S; Thawaramara T; Pataradool K; Suekwatana P
    J Obstet Gynaecol Res; 2007 Apr; 33(2):218-24. PubMed ID: 17441901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on: "Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer".
    Gibbons JA
    Clin Pharmacokinet; 2016 Jan; 55(1):131-2. PubMed ID: 26649871
    [No Abstract]   [Full Text] [Related]  

  • 12. Rockets, radiosensitizers, and RRx-001: an origin story part I.
    Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S
    Discov Med; 2016 Mar; 21(115):173-80. PubMed ID: 27115167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of castration-resistant prostate cancer.
    Lian F; Sharma NV; Moran JD; Moreno CS
    Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
    Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
    Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
    Oronsky B; Paulmurugan R; Foygel K; Scicinski J; Knox SJ; Peehl D; Zhao H; Ning S; Cabrales P; Summers TA; Reid TR; Fitch WL; Kim MM; Trepel JB; Lee MJ; Kesari S; Abrouk ND; Day RM; Oronsky A; Ray CM; Carter CA
    Expert Opin Investig Drugs; 2017 Jan; 26(1):109-119. PubMed ID: 27935336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 17. [A Case of Rapidly Progressive Metastatic Castration-Resistant Prostate Cancer : Durable Control by Early Induction of Carboplatin and Paclitaxel].
    Sunada T; Kobayashi T; Shibasaki N; Okada Y; Negoro H; Terada N; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
    Hinyokika Kiyo; 2015 Sep; 61(9):369-73. PubMed ID: 26497864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging therapies for neuroendocrine prostate cancer.
    Alabi BR; Liu S; Stoyanova T
    Pharmacol Ther; 2022 Oct; 238():108255. PubMed ID: 35905791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
    Oronsky B; Guo X; Wang X; Cabrales P; Sher D; Cannizzo L; Wardle B; Abrouk N; Lybeck M; Caroen S; Oronsky A; Reid TR
    J Med Chem; 2021 Jun; 64(11):7261-7271. PubMed ID: 34043360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.
    Huang Z; Fu J; Zhang Y
    J Med Chem; 2017 Sep; 60(18):7617-7635. PubMed ID: 28505442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.